AZ Takes Time To Answer EU Queries On Broadening Brilique Indication
CHMP Opinion On Extending Use In High-Risk CAD Patients Due In H2
You may also be interested in...
Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.